mRNA is a growing field of medicinal research with the potential to not just treat but cure disease. The complex approach to manufacturing mRNA, as well as the intracellular delivery method can bring impurity risks that impact the efficacy and safety of the drug. This article discusses analytical approaches to characterise mRNA in early-stage development to support effective therapeutic programs.


Please complete the form below to download the article